From the digestive system: loss of appetite, nausea, vomiting, dyspepsia, abdominal pain, flatulence, diarrhea, cholestatic jaundice deca durabolin before and after (especially in patients with a history of liver disease), hepatitis, gepatonekroz. Respiratory system: shortness of breath.
From the nervous system : dizziness, headache, fatigue, drowsiness, anxiety, tremor, peripheral paralgeziya (anomaly perception of feeling pain), increased sweating, increased intracranial pressure, “nightmarish” dream, confusion, depression, hallucinations, psychotic reactions, fainting;
From the senses: taste disturbances and olfactory, visual impairment (eg diplopia, change tsvetovosprnyatiya), tinnitus, hearing loss;
From the urinary system: hematuria; crystalluria (especially at low alkaline urine and diuresis);
From the Musculoskeletal System: arthralgia, asthenia, myalgia, tenosynovitis;
Allergic reactions: itching, drug fever, petechial hemorrhages (petechiae); nodular erythema, swelling of the face, throat, or vessels, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal nskroliz (Lyell’s syndrome);
From the deca durabolin before and after laboratory parameters: eosinophilia, leukopenia, granulocytopenia, anemia, thrombocytopenia; leukocytosis, thrombocytosis, haemolytic anemia, increased activity of “liver” transaminases and alkaline phosphatase, gipoprotrombpnemiya, hypercreatininemia, hyperbilirubinemia, hyperglycemia;
Others: photosensitivity, “tides” of blood to the face.
Treatment: the specific antidote is not known. Symptomatic therapy, if necessary – hemodialysis and peritoneal dialysis.
Interaction with other drugs n other forms of interaction
virtually no effect on the concentration of theophylline, oral hypoglycemic drugs, indirect anticoagulants.
Nonsteroidal anti-inflammatory drugs (except acetylsalicylic acid) increase the risk of seizures.
Oral administration in conjunction with iron-containing preparations, sucralfate and antacid preparations containing magnesium, aluminum, calcium, zinc and iron salts, lead to decreased absorption sparfloksatsnna (it should be given or for 1 to 2 hours before, or not less than 4 hours after).
Metoclopramide accelerates the absorption of sparfloksatsnna. which reduces the time to reach its maximum concentration in the plasma.
Since sparfloksatsnn can increase the duration of the QT interval. not recommended for concomitant use with drugs having the same effect: with antiarrhythmics of class Ia and III of, terfenadine, bepridilom, erythromycin. astemizole, cisapride, pentamidine. tricyclic antidepressants and phenothiazines.
When combined with other antimicrobial agents commonly observed synergism (beta-lactams, aminoglycosides, clindamycin, metronidazole); sparfloxacin can be used successfully in combination with azlocillin and ceftazidime in infections caused by Pseudomonas spp .; with mezlocillin, azlocillin and other beta-lactam antibiotics – in streptococcal infections; with penicillin-resistant betalactamase action, and vancomycin – with staphylococcal infections; metronidazole and clindamycin – In anaerobic infections.
At simultaneous application with cyclosporine sparfloksatsnna there is an increase in serum creatinine, therefore these patients should be monitored this indicator 2 times a week.
Avoid deca durabolin before and after radiation during treatment and sparfloksatsnnom within 3 days after its completion.
In order to avoid the development of crystalluria is unacceptable excess of the recommended daily dose, need adequate fluid intake and maintain acidic urine. There are anecdotal reports that the use of fluoroquinolones is accompanied by a tendon rupture shoulder, hand and Achilles tendon. When the complaints treatment should be discontinued.
During treatment with sparfloxacin should refrain from activities potentially hazardous activities that require attention and speed of mental n motor responses. steroiden kaufen
anabolika steroide kaufen
anabolika steroide kaufen